Advertisement

Behandlung der tuberkulösen Erkrankungen im Erwachsenenalter

  • Tom Schaberg
Chapter

Zusammenfassung

Zum Management der tuberkulösen Erkrankungen gehört nicht nur die korrekte Planung und Durchführung der Diagnostik, sondern auch die Überwachung der Therapie und der Therapieadhärenz sowie die Initiierung der notwendigen Umgebungsuntersuchungen. Die Behandlung einer Tuberkulose sollte daher ausschließlich von Ärztinnen oder Ärzten durchgeführt werden, die Erfahrung in der Diagnostik, der Therapie und dem Management dieser Infektionskrankheit haben.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Acocella G, Nonis A, Perna G, Patane E, Gildroni-Grassi G, Grassi C (1988) Comparative bioavailability of isoniazid, rifampicin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II.Two-month, daily administration study. Am Rev Respir Dis 138:886–890.PubMedCrossRefGoogle Scholar
  2. 2.
    Singapore Tuberculosis Service British Medical Research Council (1991) Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 143:707–712.CrossRefGoogle Scholar
  3. 3.
    Teo SK (1999) Assessment of a combined preparation of isoniazid, rifampicin, and pyrazinamide in the intial phase of chemotherapy in three 6-month regimens for smear positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 3:126–132.PubMedGoogle Scholar
  4. 4.
    Joint Committee of the British Thoracic Society (1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 53:536–548.CrossRefGoogle Scholar
  5. 5.
    American Thoracic Society (1994) Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149:1359–1374.CrossRefGoogle Scholar
  6. 6.
    Global Tuberculosis Programme (1997) Treatment of tuberculosis: guidelines for national programmes 2nd ed. World Health Organization, Geneva.Google Scholar
  7. 7.
    Moulding T, Dutt AK, Reichman LB (1995) Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 122:951–954.PubMedCrossRefGoogle Scholar
  8. 8.
    Heifets LB (1994) Antimycobacterial drugs. Semin Respir Infect 9:84–103.PubMedGoogle Scholar
  9. 9.
    Mitchison DA (1985) The action of antituberculosis drugs during short-course chemotherapy. Tubercle 66:219–225.PubMedCrossRefGoogle Scholar
  10. 10.
    Mitchison DA (1980) Basic mechanisms of chemotherapy. Chest 76S: 771–781.Google Scholar
  11. 11.
    Cole ST, Telenti A (1995) Drug resistance in Mycobacterium tuberculosis. Eur Respir J [Suppl 20]:701s–713s.Google Scholar
  12. 12.
    McClatchy JH (1986) Antimycobacterial drugs: mechanism of action, drug resistance, susceptibility testing and assays of activity in bactériologie fluids. In: Lorian VE (ed) Antibiotics in laboratory medicine. Williams and Wilkens, Baltimore, pp 161–227.Google Scholar
  13. 13.
    Mitchison DA (1998) How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2:10–15.PubMedGoogle Scholar
  14. 14.
    Musser JM (1995) Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8:496–514.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Jindani A, Aber VR, Edwards EA, Mitchison DA (1980) The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939–941.PubMedGoogle Scholar
  16. 16.
    Sirgel FA, Botha FJJ, Parkin DP, Van De Wal BW, Donald PR, Clark PK, Mitchinson DA (1993) The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 32:867–875.PubMedCrossRefGoogle Scholar
  17. 17.
    Bartmann K, Radenbach KL, Zierski M (1985) Wandlungen in den Auffassungen und der Durchführung der antituberkulösen Chemotherapie. Prax Klein Pneumol 39:397–420.Google Scholar
  18. 18.
    Bartmann K (1988) Antituberculosis drugs. Springer, Berlin Heidelberg New York.CrossRefGoogle Scholar
  19. 19.
    British Thoracic Society (1981) A controlled trial of 6-month chemotherapy in pulmonary tuberculosis. First report: results during treatment. Br J Dis Chest 75:141–153.CrossRefGoogle Scholar
  20. 20.
    British Thoracic Society (1984) A controlled trial of 6-month chemotherapy in pulmonary tuberculosis. Final report: results during the 36 month after the end of chemotherapy and beyond. Br J Dis Chest 78:330–336.CrossRefGoogle Scholar
  21. 21.
    Singapore Tuberculosis Service British Medical Research Council (1981) Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 month. Tubercle 62:95–102.CrossRefGoogle Scholar
  22. 22.
    East and Central African and British Medical Research Council (1983) Clinical controlled trial of four short-course regimens of chemotherapy (three six-month, and one eight month) for pulmonary tuberculosis. Tubercle 64:153–166.CrossRefGoogle Scholar
  23. 23.
    Snider DE, Graczyk J, Bek E, Rogowski J (1984) Supervised six-month treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 130:1091–1094.PubMedGoogle Scholar
  24. 24.
    Singapore Tuberculosis Service and British Medical Research Council (1985) Clinical trail of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 132:374–388.Google Scholar
  25. 25.
    Mitchison DA, Nunn AJ (1986) Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133:423–430.PubMedGoogle Scholar
  26. 26.
    Singapore Tuberculosis Service and British Medical Research Council (1988) Five-year follow-up of a clinical trail of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 137:1147–1150.CrossRefGoogle Scholar
  27. 27.
    Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (1997) 23. Informationsbericht, pmi Verlag, Berlin.Google Scholar
  28. 28.
    Migliori G, Raviglione MC, Schaberg T, et al. (1999) Tuberculosis management in Europe. Eur Respir J (in press).Google Scholar
  29. 29.
    Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (1995) Richtlinien zur Chemotherapie der Tuberkulose. Pneumologie 49:217–225.Google Scholar
  30. 30.
    Ferrer J (1997) Pleural tuberculosis. Eur Respir J 10:942–947.PubMedGoogle Scholar
  31. 31.
    British Thoracic Society Research Committee (1992) Six month versus nine month chemotherapy for tuberculosis of lymph nodes: preliminary results. Respir Med 86:15–19.CrossRefGoogle Scholar
  32. 32.
    Campbell IA, Ormerod LP, Friend JAR, et al. (1993) Six month versus nine month chemotherapy for tuberculosis of lymph nodes:final results. Respir Med 87:621–623.PubMedCrossRefGoogle Scholar
  33. 33.
    American Thoracic Society (1990) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 142:940–953.CrossRefGoogle Scholar
  34. 34.
    Medical Research Council Working Party on Tuberculosis of the Spine (1993) Controlled trial of short-course regimens of chemotherapy in ambulatory treatment of spinal tuberculosis. J Bone Joint Surg 75:240–248.Google Scholar
  35. 35.
    Dutt AK, Moers D, Stead WW (1986) Short course chemotherapy for extrapulmonary tuberculosis. Ann Intern Med 107:7–12.CrossRefGoogle Scholar
  36. 36.
    Humphries M (1992) The management of tuberculous meningitis. Thorax 47:577–581.PubMedCrossRefGoogle Scholar
  37. 37.
    Pantel AM, McKeon J (1995) Avoidance and management of adverse reactions to antituberculosis drugs. Drug Safety 12:1–25.CrossRefGoogle Scholar
  38. 38.
    Van den Brande P, Van Steenbergen W, Vervoort G, Demedts M (1995) Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 152:1705–1708.PubMedCrossRefGoogle Scholar
  39. 39.
    Ormerod LPf Skinner C, Wales JM (1996) Hepatotoxicity of antituberculosis drugs. Thorax 51:111–113.PubMedCrossRefGoogle Scholar
  40. 40.
    Steele MA, Burk RF, DesPrez RM (1991) Toxic hepatitis with isoniazid and rifampin. Chest 99:465–471.PubMedCrossRefGoogle Scholar
  41. 41.
    Schaberg T, Rebhan K, Lode H (1996) Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9:2026–2030.PubMedCrossRefGoogle Scholar
  42. 42.
    Grange GM, Winstanley PA, Davies PDO (1994) Clinically significant drug interaction with antituberculosis drugs. Drug Safety 11:242–251.PubMedCrossRefGoogle Scholar
  43. 43.
    Edwards OM, Courtney-Evans RJ, Galley JM, et al. (1974) Changes in cortisol metabolism following rifampicin therapy. Lancet II 548–551.Google Scholar
  44. 44.
    Centers for Disease Control (1998) Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 47 (RR-20):1–58.Google Scholar
  45. 45.
    Havlir DV, Barnes PF (1999) Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340:367–373.PubMedCrossRefGoogle Scholar
  46. 46.
    Centers for Disease Control (1996) Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 45:921–925.Google Scholar
  47. 47.
    Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC (1991) Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 324:289–294.PubMedCrossRefGoogle Scholar
  48. 48.
    Narita M, Askin D, Höhender ES, Pitchenik AE (1998) Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 157:161.Google Scholar
  49. 49.
    Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328:521–526.PubMedCrossRefGoogle Scholar
  50. 50.
    Ormerod LP (1997) Chemotherapy of tuberculosis. In: Wilson R (ed) Tuberculosis. Eur Respir Monograph: European Respiratory Society 4:273–297.Google Scholar
  51. 51.
    Winstanley PA (1998) Clinical pharmacology of antituberculosis drugs. In: Davies PDO (ed) Clinical Tuberculosis. Chapman & Hall, London, pp 225–242.Google Scholar
  52. 52.
    Anonymous (1980) Tuberculosis in patients having dialysis. Br Med J 1:349.Google Scholar
  53. 53.
    Snider DE, Layde PM, Johnson MW, Lyle MA (1980) Treatment of tuberculosis during pregnancy. Am Rev Repir Dis 122:65–79.Google Scholar
  54. 54.
    Davidson PT (1995) Managing tuberculosis during pregnancy. Lancet 346:199–200.PubMedCrossRefGoogle Scholar
  55. 55.
    Weis SE, Slocum PC, Biais FX, et al. (1994) The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 330:1179–1184.PubMedCrossRefGoogle Scholar
  56. 56.
    China Tuberculosis Control Collaboration (1996) Results of directly observed shortcourse chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet 347:358–362.CrossRefGoogle Scholar
  57. 57.
    Moore RD, Chaulk CP, Griffiths R, et al. (1996) Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 154:1013–1019.PubMedCrossRefGoogle Scholar
  58. 58.
    Crofton J, Chaulet P, Maher D, et al. (1997) Guidelines for the management of drugresistant tuberculosis. World Health Organization, Geneva.Google Scholar
  59. 59.
    Centers for Disease Control (1993) Initial therapy for tuberculosis in the area of multi-drug-resistance. MMWR 42:1–8.Google Scholar
  60. 60.
    World Health Organization (1994) Tuberculosis programme: framework for effective tuberculosis control. World Health Organization, Geneva.Google Scholar
  61. 61.
    Pablos-Mendez A, Laszlo A, Bustreo F, et al. (1997) Anti-tuberculosis drug resistance in the world. WHO Global Tuberculosis Programme, Geneva.Google Scholar
  62. 62.
    Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 338:1641.PubMedCrossRefGoogle Scholar
  63. 63.
    Iseman MD (1993) Treatment of multidrugresistant tuberculosis. N Engl J Med 329:784–791.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Tom Schaberg
    • 1
  1. 1.Lungenklinik, Diakoniekrankenhaus RotenburgRotenburg/WümmeDeutschland

Personalised recommendations